TSE:HLS HLS Therapeutics (HLS) Stock Forecast, Price & News C$4.30 0.00 (0.00%) (As of 06/5/2023 ET) Add Compare Share Share Today's RangeC$4.29▼C$4.3050-Day RangeC$4.15▼C$6.4552-Week RangeC$4.12▼C$14.86Volume4,100 shsAverage Volume22,258 shsMarket CapitalizationC$139.11 millionP/E RatioN/ADividend Yield4.65%Price TargetC$24.25 ProfileProfileAnalyst RatingsChartCompetitorsDividendEarningsInsider TradesHeadlinesSocial MediaProfileAnalyst RatingsChartCompetitorsDividendEarningsInsider TradesHeadlinesSocial Media HLS Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside360.5% UpsideC$19.80 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingAcquiring SharesC$11,250 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 stars 3.3 Analyst's Opinion Consensus RatingHLS Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of C$19.80, HLS Therapeutics has a forecasted upside of 360.5% from its current price of C$4.30.Amount of Analyst CoverageHLS Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for HLS. Previous Next 1.7 Dividend Strength Dividend LeadershipHLS Therapeutics is a leading dividend payer. It pays a dividend yield of 4.61%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthHLS Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HLS. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows1 people have added HLS Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, HLS Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$11,250.00 in company stock and sold C$0.00 in company stock.Percentage Held by InsidersOnly 6.16% of the stock of HLS Therapeutics is held by insiders.Percentage Held by Institutions67.67% of the stock of HLS Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of HLS Therapeutics is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HLS Therapeutics is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHLS Therapeutics has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About HLS Therapeutics (TSE:HLS) StockHLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.Read More Receive HLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HLS Stock News HeadlinesMay 26, 2023 | americanbankingnews.comHLS Therapeutics Inc. (TSE:HLS) Senior Officer Purchases C$11,250.00 in StockMay 25, 2023 | baystreet.caThis Healthcare Stock Just Hit a 52-Week Low: Is it Time to Buy?June 6, 2023 | Edge On The Street (Ad)ChatGPT Is Already "Old School"As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.May 16, 2023 | theglobeandmail.comClosing Bell: Hls Therapeutics Inc flat on Tuesday (HLS)May 11, 2023 | markets.businessinsider.comHLS Therapeutics Inc (HLS) Receives a Buy from Stifel NicolausMay 11, 2023 | finance.yahoo.comHLS Therapeutics Announces Q1 Fiscal 2023 Financial ResultsMay 4, 2023 | theglobeandmail.comClosing Bell: Hls Therapeutics Inc down on Thursday (HLS)April 28, 2023 | theglobeandmail.comClosing Bell: Hls Therapeutics Inc up on Thursday (HLS)June 6, 2023 | Edge On The Street (Ad)ChatGPT Is Already "Old School"As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.April 25, 2023 | americanbankingnews.comHLS Therapeutics Inc. (TSE:HLS) Declares $0.05 Quarterly DividendApril 22, 2023 | theglobeandmail.comClosing Bell: Hls Therapeutics Inc down on Friday (HLS)April 21, 2023 | msn.comSTIFEL CANADA Maintains HLS Therapeutics (HLS) Buy RecommendationApril 21, 2023 | theglobeandmail.comClosing Bell: Hls Therapeutics Inc flat on Thursday (HLS)April 20, 2023 | theglobeandmail.comClosing Bell: Hls Therapeutics Inc down on Wednesday (HLS)April 19, 2023 | seekingalpha.comHLS Therapeutics appoints CEOApril 18, 2023 | theglobeandmail.comClosing Bell: Hls Therapeutics Inc down on Monday (HLS)April 17, 2023 | finance.yahoo.comHLS Therapeutics Inc. (TSE:HLS) Not Lagging Industry On Growth Or PricingApril 17, 2023 | markets.businessinsider.comHLS Therapeutics Names Craig Millian CEO - Quick FactsApril 17, 2023 | finance.yahoo.comHLS Therapeutics Announces CEO TransitionApril 15, 2023 | theglobeandmail.comClosing Bell: Hls Therapeutics Inc up on Friday (HLS)April 13, 2023 | theglobeandmail.comClosing Bell: Hls Therapeutics Inc up on Wednesday (HLS)April 12, 2023 | theglobeandmail.comClosing Bell: Hls Therapeutics Inc down on Tuesday (HLS)April 11, 2023 | theglobeandmail.comClosing Bell: Hls Therapeutics Inc up on Monday (HLS)April 5, 2023 | theglobeandmail.comClosing Bell: Hls Therapeutics Inc up on Tuesday (HLS)March 31, 2023 | theglobeandmail.comHLS Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (HLS)March 21, 2023 | americanbankingnews.comHLS Therapeutics Inc. (TSE:HLS) Forecasted to Post Q1 2024 Earnings of ($0.05) Per ShareMarch 20, 2023 | finance.yahoo.comHLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05See More Headlines HLS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HLS Company Calendar Ex-Dividend for 3/15 Dividend1/30/2023Dividend Payable3/15/2023Last Earnings3/16/2023Ex-Dividend for 6/15 Dividend4/27/2023Today6/05/2023Dividend Payable6/15/2023Next Earnings (Estimated)8/10/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolTSE:HLS CUSIPN/A CIKN/A Webwww.hlstherapeutics.com Phone647-495-9000FaxN/AEmployees92Year FoundedN/APrice Target and Rating Average Stock Price ForecastC$19.80 High Stock Price ForecastC$26.50 Low Stock Price ForecastC$15.00 Forecasted Upside/Downside+464.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)C($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-25,770,000.00 Net Margins-41.79% Pretax MarginN/A Return on Equity-18.55% Return on Assets-3.42% Debt Debt-to-Equity Ratio80.07 Current Ratio1.48 Quick Ratio1.01 Sales & Book Value Annual SalesC$61.67 million Price / Sales2.26 Cash FlowC$0.28 per share Price / Cash Flow15.22 Book ValueC$3.67 per share Price / Book1.17Miscellaneous Outstanding Shares32,350,000Free FloatN/AMarket CapC$139.11 million OptionableNot Optionable Beta0.88 Key ExecutivesMr. Gregory David Gubitz B.A. (Age 66)L.L.B., LL.B, Co-Founder & Chairman Comp: $289.94kMr. Gilbert Godin (Age 64)Co-Founder, CEO & Director Comp: $857.38kMr. Tim Hendrickson M.B.A. (Age 51)Chief Financial Officer Comp: $402.33kMr. Sanjiv Sharma (Age 67)Chief Commercial Officer Comp: $486.69kMr. Ryan C. Lennox B.A. (Age 42)J.D., Sr. VP of Legal, HR & Compliance and Corp. Sec. David Spence (Age 55)Corp. Controller More ExecutivesKey CompetitorsMedexus PharmaceuticalsCVE:MDPCipher PharmaceuticalsTSE:CPHOrganigramTSE:OGIGreen Organic DutchmanTSE:TGODDelta 9 CannabisCVE:NINEView All CompetitorsInsidersTim HendricksonBought 2,500 shares on 5/19/2023Total: C$11,250.00 ($4.50/share)View All Insider Transactions HLS Stock - Frequently Asked Questions Should I buy or sell HLS Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HLS shares. View HLS analyst ratings or view top-rated stocks. What is HLS Therapeutics' stock price forecast for 2023? 3 equities research analysts have issued 1 year price objectives for HLS Therapeutics' stock. Their HLS share price forecasts range from C$15.00 to C$26.50. On average, they anticipate the company's share price to reach C$19.80 in the next year. This suggests a possible upside of 360.5% from the stock's current price. View analysts price targets for HLS or view top-rated stocks among Wall Street analysts. How have HLS shares performed in 2023? HLS Therapeutics' stock was trading at C$9.83 at the beginning of the year. Since then, HLS shares have decreased by 56.3% and is now trading at C$4.30. View the best growth stocks for 2023 here. When is HLS Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our HLS earnings forecast. How were HLS Therapeutics' earnings last quarter? HLS Therapeutics Inc. (TSE:HLS) announced its quarterly earnings data on Thursday, March, 16th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.18. The business had revenue of $21.28 million for the quarter, compared to analyst estimates of $22.56 million. HLS Therapeutics had a negative net margin of 41.79% and a negative trailing twelve-month return on equity of 18.55%. How often does HLS Therapeutics pay dividends? What is the dividend yield for HLS Therapeutics? HLS Therapeutics announced a quarterly dividend on Thursday, April 27th. Stockholders of record on Thursday, June 15th will be paid a dividend of 0.05 per share on Thursday, June 15th. This represents a $0.20 annualized dividend and a dividend yield of 4.65%. The ex-dividend date is Thursday, April 27th. Read our dividend analysis for HLS. Is HLS Therapeutics a good dividend stock? HLS Therapeutics (TSE:HLS) pays an annual dividend of C$0.20 per share and currently has a dividend yield of 4.61%. HLS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Read our dividend analysis for HLS. What other stocks do shareholders of HLS Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other HLS Therapeutics investors own include Cargojet (CJT), Fairfax Financial (FFH), Fortis (FTS), Aurora Cannabis (ACB), Aphria (APHA), Alimentation Couche-Tard (ATD.B), BlackBerry (BB), BCE (BCE), Bank of Montreal (BMO) and Bank of Nova Scotia (BNS). What is HLS Therapeutics' stock symbol? HLS Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "HLS." How do I buy shares of HLS Therapeutics? Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is HLS Therapeutics' stock price today? One share of HLS stock can currently be purchased for approximately C$4.30. How much money does HLS Therapeutics make? HLS Therapeutics (TSE:HLS) has a market capitalization of C$139.11 million and generates C$61.67 million in revenue each year. The company earns C$-25,770,000.00 in net income (profit) each year or C($1.12) on an earnings per share basis. How can I contact HLS Therapeutics? The official website for the company is www.hlstherapeutics.com. The company can be reached via phone at 647-495-9000. This page (TSE:HLS) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HLS Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.